Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

William Blair Downgrades Mandiant to Market Perform

William Blair analyst Jonathan Ho downgrades Mandiant (NASDAQ:MNDT) from Outperform to Market Perform.

byBenzinga Newsdesk

March 8, 2022

1 minute read

William Blair analyst Jonathan Ho downgrades Mandiant (NASDAQ:MNDT) from Outperform to Market Perform.

Barclays Upgrades Diamondback Energy to Overweight, Lowers Price Target to $160

By Benzinga Newsdesk

Today, 10:20 PM

Barclays analyst Jeanine Wai upgrades Diamondback Energy (NASDAQ:FANG) from Equal-Weight to Overweight and lowers the price target from $162 to $160.

FANG

FDA
News

FDA Says Recommended Pfizer Revise Recall To Consumer Level In Order To Take Into Account Product Currently On Market, Says Co. Has Not Yet Done So

By Michael Horton

Today, 10:20 PM

-Reuters

PFE

FDA
News

Acurx Announces New Data Presentations From Ongoing Ph2 Clinical Trial Program Of Ibezapolstat For CDI At 16th Biennial Congress Of Anaerobe Society of America

By Benzinga Newsdesk

Today, 10:20 PM

New data link beneficial microbiome changes in Ph2a CDI patients to earlier results from Ph1 healthy volunteers to predict potential anti-recurrence properties of ibezapolstat New in vitro data show ibezapolstat is

ACXP

CommScope Holding Co Q2 Adj. EPS $0.43 Misses $0.44 Estimate, Sales $2.19B Beat $2.16B Estimate

By Benzinga Newsdesk

Today, 10:20 PM

CommScope Holding Co (NASDAQ:COMM) reported quarterly earnings of $0.43 per share which missed the analyst consensus estimate of $0.44 by 2.27 percent. This is a 34.37 percent increase over earnings of $0.32 per share

COMM

William Blair Downgrades Mandiant to Market Perform

Related Posts

Barclays Upgrades Diamondback Energy to Overweight, Lowers Price Target to $160

FDA Says Recommended Pfizer Revise Recall To Consumer Level In Order To Take Into Account Product Currently On Market, Says Co. Has Not Yet Done So

Acurx Announces New Data Presentations From Ongoing Ph2 Clinical Trial Program Of Ibezapolstat For CDI At 16th Biennial Congress Of Anaerobe Society of America

CommScope Holding Co Q2 Adj. EPS $0.43 Misses $0.44 Estimate, Sales $2.19B Beat $2.16B Estimate